50 results on '"Pandey, Manu"'
Search Results
2. Impact of Race and Age and their Interaction on Survival Outcomes in Patients With Diffuse Large B-Cell Lymphoma
3. Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy
4. A Finite Element Analysis to Study the Effect of Various Loading Conditions on the Intervertebral Disc in L4–L5 Section of Lumbar Spine
5. Comparing thermal stress reduction strategies that influence MDSC accumulation in tumor bearing mice
6. Safety and feasibility of outpatient CAR-T therapy: A single center analysis.
7. Hypothyroidism and Goiter in a Young Male with Suspected Dietary Iodine Deficiency Followed by Thyrotoxicosis After Iodine Supplementation
8. A Finite Element Analysis to Study the Effect of Various Loading Conditions on the Intervertebral Disc in L4–L5 Section of Lumbar Spine
9. Impact of primary organ site of involvement by peripheral T‐cell lymphoma not otherwise specified on survival
10. Endocrine Toxicities of Immunotherapy
11. Contributors
12. Neurological Toxicities of Immunotherapy
13. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in Jehovah's witness patients
14. Figure S1 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
15. Table S1 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
16. β2-AR Signaling Enhances MDSC Survival through Metabolic Reprograming and Impairs Therapeutic Efficacy in Hematologic Malignancies
17. Heart Failure: A Paraneoplastic Manifestation of Renal Cell Carcinoma – Reversed With Pazopanib
18. Capítulo 20 - Toxicidades neurológicas de la inmunoterapia
19. capítulo 18 - Toxicidades endocrinas de la inmunoterapia
20. Abstract CT568: β-2 adrenergic receptor (AR): Another immune checkpoint (IC)" A phase II clinical trial of propranolol (P) with pembrolizumab (Pem) in patients with unresectable stage III and stage IV melanoma
21. Potential netting benefits from expanded central clearing in Canada’s fixed-income market
22. Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms
23. COVID-19 crisis: Liquidity management at Canada’s largest public pension funds
24. Prediction of Life-threatening and Disabling Bleeding in Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
25. Chapter 20 - Neurological Toxicities of Immunotherapy
26. Chapter 18 - Endocrine Toxicities of Immunotherapy
27. Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
28. Mechanism‐based treatment of cancer with immune checkpoint inhibitor therapies
29. Diffuse large B-Cell lymphoma associated with paraneoplastic Guillain–Barré syndrome: A diagnostic and therapeutic challenge
30. SAT-131 Asymptomatic Severe Hypoglycemia with Lactic Acidosis in a Case of Non-Hodgkin’s Lymphoma - an Unusual Phenomenon of Hyper-Warburgism
31. Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms.
32. The side effects of immune checkpoint inhibitor therapy on the endocrine system.
33. Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors
34. Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A Single Center Retrospective Analysis
35. What potential is there for LSD1 inhibitors to reach approval for AML?
36. Abstract 4057: Measurement of myeloid derived suppressor cells (MDSC), T regulatory cells (Treg), CD8+and CD4+T-cells, and cytokines/chemokines in patients with metastatic melanoma treated with pembrolizumab and propranolol
37. Metastatic sarcomatoid renal cell carcinoma treated with immune checkpoint inhibitors
38. Colaboradores
39. Mechanism of resistance to immune checkpoint inhibitors
40. Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib
41. Contributors
42. Challenges faced when identifying patients for combination immunotherapy
43. Abstract 620: Tumor microenvironment heterogeneity is not identified across multiple histologically similar tumors from the same patient
44. Algorithmic prediction of response to checkpoint inhibitors: Hyperprogressors versus responders.
45. Clinical and biochemical parameters as predictors of response to checkpoint inhibitors (CPI): A single institution experience.
46. The inflamed phenotype in PD-L1 negative non-small cell lung cancer (NSCLC) and response to checkpoint inhibitors
47. The inflamed phenotype in PD-L1 negative melanoma and response to checkpoint inhibitors.
48. Diffuse large B-Cell lymphoma associated with paraneoplastic Guillain–Barré syndrome: A diagnostic and therapeutic challenge
49. Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib
50. 18 F-FLT PET and Blood-based Biomarkers for Identifying Gastrointestinal Graft versus Host Disease after Allogeneic Cell Transplantation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.